top of page
SFTCG Web Banner.png
A workshop on Gene Editing and Cell Therapy took place on 21 & 22 March 2024 in Nantes



Thursday 21 March: SFTCG Academy

This Academy-type programme, including one mentoring talk, will give 8 students the opportunity to present their work on any topic as long as it falls under the gene and cell therapy umbrella. This event is free of charge for SFTCG student members and can either be attended on its own or combined with the Theme Day to be held on 22 March.

Students can submit an abstract for this Academy day on any topic as long as it is gene and cell therapy related. We will select the top 8 abstracts submitted regardless of the categories. Of course abstracts in gene editing or cell therapy are more likely to be selected for the Theme Day rather than for the Academy.

Registration and light lunch

Chair: Els Verhoeyen

INV01  Zoltan Ivics, Paul Ehrlich Insitute, Langen

Digging in the Dirt: How Archeogenetics and Synthetic Biology Impacted Gene Therapy

14.00-15.30 (10 minutes presentation and 20 minutes for questions and mentoring)  
Oral presentations from students
Chairs: Sophie Gomez, Capucine Trollet, Els Verhoeyen


OR01  Clémence Lièvre, TaRGeT, Nantes

Skeletal muscle organoids for preclinical gene therapy with recombinant AAV vectors


OR02  Clément Morival, TaRGeT, Nantes

Modelling Stargardt disease using three-dimensional retinal organoids

OR03  Carine Bourdais, IRBM, Montpellier

Combined cellular and gene therapy to treat primary ciliary dyskinesia.

Coffee Break

16.00-18.00 (10 minutes presentation and 20 minutes for questions and mentoring)  
Oral presentations from students

Chairs: Olivier Négre, Françoise Piguet


OR05  Manon Lucas, TaRGeT, Nantes

High systemic dosing of AAV9 vectors:  a relevant rat model to study the impact of vector immunogenicity in the liver

OR06  Laurie Lacombe, Généthon Evry

NHEJ inhibition increases homology-mediated AAV integration in hematopoietic cells

OR07  Jean Baptiste Ducloyer, TaRGeT, Nantes

Study of retinal microglial cells after sub-retinal injection of recombinant AAV in pigs 

OR08  Marie Esnard, GEPEA – St Nazaire / TaRGeT, Nantes

Development of an AAV bioproduction technological platform in microalgae    


Friday 22 March: Theme Day


Transparent Logo.png


Transparent Logo.png

(10 minutes presentation and 5 minutes for questions)  

Session 1
Chair: François Moreau Gaudry, Caroline Le Guiner

INV02  Carine Giovannangeli, 

INV03  Annarita Miccio, Institut Imagine

Genome editing approaches for hematopoietic disorders


OR09  Paloma Navas Navarro, Généthon Evry

Treatment of myotonic dystrophy type 1 with CRISPR/Cas9 

OR10  Margaux Melka, Institut des Neurosciences de Grenoble

Mutation independent CRISPR/Cas9-induced allele deletion results in vitro in a functional benefit for dominant RYR1 mutation 


Coffee Break

Transparent Logo.png

(10 minutes presentation and 5 minutes for questions)  

Session 2
Chair: Mario Amendola, Matthias Titeux

INV04  Maria Silvia Roman Azcona , University of Freiburg
Epigenome editing of immune checkpoints in CAR T cells

INV05  François Moreau Gaudry, University of Bordeaux

Genotoxicity risk induced by CRISPR-Cas9: understanding and preventing i


OR11  Juliette Varin,TaRGeT, Nantes

Homology-independent targeted integration (HITI) as possible treatment for Stargardt disease

OR12  Hugo Malki, Institut de la Vision, Paris

Delivery of Cas9 ribonucleoprotein to the retina of mice with Retinitis pigmentosa 



Transparent Logo.png


Transparent Logo.png

14.00-15.30 (10 minutes presentation and 5 minutes for questions)  
Session 3
Chair: Christelle Monville, Leila Maouche Chrétien

INV08  Philippe Menasché, Université Paris Cité.
Cell therapy for cardiac diseases: sucesses and remaining challenges

INV09  Karl Rouger, PanTher - INRAe, ONIRIS, UMR 703 - Nantes
Muscle repair potential of adult stem cells through different modes of action

OR13  Isabelle Prost, Promega, France

New technologies for CAR-T characterization and potency testing 

OR14  Allwyn Pereira, TaRGeT, Nantes

Multiomic analyses reveals epigenome remodeling and transcriptional co-factors as critical determinants for neuronal cell therapy 

Transparent Logo.png

Coffee Break

Transparent Logo.png

16.00-17.30 (10 minutes presentation and 5 minutes for questions)  
Session 4
Chair: Oumeya Adjali, Emmanuel Payen

INV11 Jérémie Martinet, Rouen University
Irradiation as an adjuvant for CAR-T cell therapy

INV12  Vasco Meneghini, Hospital San Raffaele, Milano
Tackling neurodegeneration with neural stem and progenitor cells

OR15  Camille Le Guen, CHU Nantes

Can academic structures improve access to CAR-T cells?


Transparent Logo.png
bottom of page